## BACKGROUND. Two new prostate cancer markers, free-prostate specific antigen (f-PSA) and prostate specific membrane antigen (PSMA) were recently introduced. This report summarizes a prospective two-year multicenter test of their diagnostic or prognostic capabilities. Total PSA was also measured.
Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma
โ Scribed by Sam S Chang; Victor E Reuter; W.D.W Heston; Paul B Gaudin
- Book ID
- 117263608
- Publisher
- Elsevier Science
- Year
- 2001
- Tongue
- English
- Weight
- 298 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0090-4295
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
ated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA)
Decalcified bone marrow biopsies containing metastatic tumor from 36 patients were stained for prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) using the avidin biotin compIex (ABC) immunoperoxidase technique. Of these patients, 22 had known prostate primaries, ten had known nonp
## Background: Prostate-specific membrane antigen (psma) is a novel prostate biomarker overexpressed in poorly differentiated and metastatic prostate carcinomas and apparently upregulated following hormone-ablation therapy. psma appears to be a satisfactory target for antibody-directed imaging of p